JBJames R. Bateman

James R. Bateman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James R. Bateman has a total of 199 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plasma biomarker levels and cognitive decline in a heterogenous community-based cohort with multiple comorbidities

    by Marc D. Rudolph, Julia R. Bacci, Jillian K. Lee, Sarah A. Gaussoin, James R. Bateman, Timothy M. Hughes, Shannon L. Risacher, Laura D. Baker, Goldie S. Byrd, Courtney L. Sutphen, et al.

    INTRODUCTION: Knowledge about how Alzheimer’s disease (AD) and AD-related dementia (AD/ADRD) plasma biomarkers relate to global and domain-specific cognitive functioning across diagnostic groups remains limited, particularly in heterogeneous, community-dwelling populations with multiple comorbidities. METHODS: We evaluated associations between baseline plasma biomarker levels (Aβ42/40, p-tau181, p-tau217, NfL, GFAP) and cognitive performance at baseline and longitudinally (up to 7 years). Participants (n=590) enrolled in the Wake Forest Alzheimer’s Disease Research Center Clinical Core (314 cognitively unimpaired [CU]; 206 mild cognitive impairment [MCI]; and 70 dementia) completed annual cognitive assessments including the Uniform Data Set (UDSv3; NACC). Domain-specific cognitive composites including memory, executive function, attention, language, visuospatial ability, and phonemic fluency, as well as a modified Preclinical Alzheimer’s Cognitive Composite (PACC5), were evaluated. General linear and mixed-effects models were adjusted for demographics (age, sex, race, education), APOE-ε4 status, comorbidities (estimated glomerular filtration rate; BMI), and cardiometabolic health factors (hypertension, diabetes). Effect modification by cognitive diagnosis was evaluated. RESULTS: Baseline plasma biomarkers, particularly p-tau217, were associated with poorer baseline cognitive performance and greater longitudinal decline on the PACC5 and all cognitive domains assessed, except phonemic fluency (strongest for memory). Post-hoc analyses indicated associations between plasma biomarker levels and cognition were generally more pronounced in MCI compared with CU participants. Effect modification by baseline cognitive status was limited and attenuated when all biomarkers were modeled simultaneously. Comorbidities and cardiometabolic factors modified select associations. DISCUSSION: Plasma AD/ADRD biomarkers, particularly p-tau217, were associated with cognitive impairment and decline in a heterogenous community cohort. HIGHLIGHTS: The WF ADRC is a clinically heterogeneous, comorbidity-rich community-dwelling cohort Plasma AD/ADRD biomarkers were associated with poorer baseline cognition and longitudinal cognitive decline Associations were strongest for the PACC5 composite and memory-related cognitive domains p-tau217 provided the most robust biomarker signal across models

  • Open Access

    Evaluation of an in vivo biomarker of arteriolosclerosis (ARTS) and its associations with cognition and multimodal ATN(V) biomarkers in a cardiometabolic-risk enriched community cohort

    by Marc D. Rudolph, Samuel N. Lockhart, Melissa R. Rundle, Richard A. Barcus, Kathryn A. Alphin, James R. Bateman, Kiran K. Solingapuram Sai, Michelle M. Mielke, Thomas C. Register, Suzanne Craft, et al.

    Objective: To evaluate associations between an in vivo (MRI) marker of arteriolosclerosis (ARTS) and multimodal neuroimaging and plasma ATN(V) biomarkers. Methods: Among 238 participants with both amyloid and tau PET scans within one year of MRI, we examined multivariable adjusted models relating ARTS with structural MRI (cortical thickness/volume, white matter hyperintensities [WMH]), diffusion MRI (fractional anisotropy [FA], mean diffusivity [MD], NODDI free water [FW]), cerebral blood flow, plasma biomarkers (p-tau217, A β 42/40, neurofilament light, glial fibrillary acidic protein [GFAP]), and PET imaging. Results: As expected, ARTS was most strongly linked to age and greater WMH burden and diffusion-based indices of microstructural disruption (FA, MD, FW). ARTS was elevated in ATN biomarker-positive groups (highest in A+T+N+) and was associated with greater neurodegeneration and higher plasma biomarker levels, GFAP in particular. Conclusions: ARTS relates to other markers of vascular brain injury, neurodegeneration, amyloid and tau pathology within the ATN(V) framework, and inflammation. Highlights: ARTS scores are elevated in ATN-positive individuals, most prominently in A+T+N+ ARTS may exert stage-specific effects on neurodegeneration rather than track A/T burden. Strong ARTS-GFAP association suggests role of astroglial activation in vascular-related neurodegeneration Findings underscore the importance of vascular contributions to AD/ADRD pathophysiology, especially in high-cardiometabolic-risk populations

  • Open Access

    Platelets from older adults exhibit differences in mitochondrial function associated with impaired glucose metabolism

    by Gargi Mahapatra, Zhengrong Gao, James R. Bateman, Samuel Neal Lockhart, Jaclyn Bergstrom, Jemima Elizabeth Piloso, Suzanne Craft, Anthony J. A. Molina

    Impaired glucose tolerance (IGT) and insulin resistance (IR), including prediabetes and diabetes, increase risk of developing age-related disorders, such as cardiovascular disorders, kidney disorders, and Alzheimer’s disease. We analyzed mitochondrial bioenergetics of platelets collected from 208 adults, 55 years and older, with IGT and IR and without normoglycemic (NG). Platelets from IGT participants exhibited unique mitochondrial bioenergetic profiles exemplified by higher mitochondrial respiration compared with NG. IGT platelets exhibited higher glucose-dependent maximal respiration (Max) and spare respiratory capacities (SRCs) and higher fatty acid oxidation (FAO)-dependent maximal coupled (MaxOXPHOS) and uncoupled (maximal electron transport system) respiration compared with NG. Correlating mitochondrial bioenergetics from all 208 participants with measures of glucose tolerance (oral glucose tolerance test values measured 120 min after glucose administration, and oral glucose tolerance test area under the curve), and historical glucose measures [hemoglobin A1 (HbA1c)] revealed significant positive associations. Most associations were unaltered with age, sex, and body mass index adjustments. Examining NG and IGT participants separately, we found platelet respiration and HbA1c exhibited positive association in NG participants. Significant positive associations emerged between platelet SRC, FAO, FAO+CI (oxygen flux due to FAO + complex I activities), and HbA1c. No significant associations were observed in the IGT group. Given the utilization of blood-based mitochondrial bioenergetic profiling strategies in clinical research, this work provides new insights into the clinical features of IR that can affect platelet mitochondrial bioenergetics.

  • Physiological Changes Linked with Alzheimer’s Disease and Related Dementias

    by Ameanté Payen, James R. Bateman, Dana Miller, Sneha Dhanavanthri Muralidhara, Jeanette M. Bennett

  • A pilot study evaluating early psychosocial risk and brain health outcomes in Veterans with mild TBI

    by Victoria O’COnnor, James R. Bateman, Anna T. Magnante, Katherine M. Craig, Sarah L. Martindale

    The goal of this pilot study was to describe the relationship between early psychosocial risk (i.e., adverse childhood experiences, neighborhood disadvantage, multiple relocations) and brain health outcomes among Veterans with mild TBI. Veterans (N = 76) with mild TBI participated at an outpatient VA. This cross-sectional study involved the collection and analysis of retrospective self-report data and neuropsychological tests. Interviews and surveys included the Clinician-Administered PTSD Scale for DSM-5, Mid-Atlantic MIRECC Assessment of Traumatic Brain Injury, Childhood Experiences Survey, Neurobehavioral Symptom Inventory, PTSD Checklist for DSM-5, and Patient Health Questionnaire. Neuropsychological tests included the California Verbal Learning Test-3, Controlled Oral Word Association and Animal Naming, Stroop, Trail Making Test, and WAIS-IV subtests (Digit Span, Letter Number Sequencing). Global deficit scores were calculated. Participants endorsed a wide range of psychosocial risk factors. Cognitive functioning was generally intact. There were few significant relationships between early psychosocial risk and outcomes. Early psychosocial risk was not associated with mental health or cognitive functioning.


  • Antiamyloid Monoclonal Antibodies in Alzheimer’s Disease Part 2: Challenges in Dementia Care Delivery System Logistics

    by Tara C. Carlisle, James R. Bateman, Yanghong Yang, Christian Lachner, Melissa D. Stockbridge, Laura A. Flashman, Zeina Chemali, Nasir Alzbeidi, Peter S. Pressman, Anne-Marie Osibajo, et al.

    Alzheimer's disease (AD) is a common neurodegenerative illness affecting nearly 7 million people in the United States. Until 2023, no disease-targeting pharmacotherapeutics were widely available outside of research studies. With relatively recent regulatory approval and increasing availability of antiamyloid therapies (AATs) in the United States, management of AD is rapidly shifting from symptomatic and supportive care alone to treatments aimed at disease modification. Appropriate selection of patients for AATs can be challenging and varies among health care settings and systems despite published appropriate-use recommendations. The first of this two-part Treatment in Behavioral Neurology & Neuropsychiatry series from the American Neuropsychiatric Association Dementia Special Interest Group addresses the challenges with patient selection. In this second part, the authors offer dementia-focused health care vignettes to illustrate challenges with AAT delivery encountered in different settings and discuss emerging logistical issues associated with delivery of dementia-focused care based on AAT protocols.


  • Antiamyloid Monoclonal Antibodies in Alzheimer’s Disease, Part 1: Patient Selection

    by James R. Bateman, Tara C. Carlisle, Yanghong Yang, Christian Lachner, Melissa D. Stockbridge, Laura A. Flashman, Zeina Chemali, Nasir Alzbeidi, Peter S. Pressman, Anne-Marie Osibajo, et al.

    The availability of monoclonal antibodies directed against amyloid beta, for use as disease-modifying therapies for Alzheimer's disease (AD), represented a major shift in the field of AD research and treatment. U.S. Food and Drug Administration approvals for the monoclonal antibody-based medications lecanemab and, more recently, donanemab provide clinicians with two antiamyloid therapy (AAT) options for targeting early symptomatic AD. The emergence of AAT has made careful biomarker-informed diagnosis of AD paramount, which was once reserved for highly specialized centers and research settings. Patient selection is complex, and although appropriate-use recommendations have been published, clinicians caring for patients with AD across the United States face uncertainty when trying to align clinical trial criteria, appropriate-use recommendations, and real-world patients in the clinic. Practical issues in patient selection as well as health care and systemic challenges in the implementation of AAT are considered in part 1 and part 2, respectively, of this two-part Treatment in Behavioral Neurology & Neuropsychiatry commentary on these therapies from the American Neuropsychiatric Association Dementia Special Interest Group.


  • Open Access

    Heart rate variability during routine cognitive testing: preliminary analyses of time and frequency domain metrics

    by James R. Bateman, Christopher L. Schaich, Hossam A Shaltout, Kathryn H Alphin, Samuel N. Lockhart, Timothy M. Hughes, Kristen A Lindquist, Suzanne Craft

    Background: Early autonomic function changes in Alzheimer’s disease (AD) may represent a biomarker for early affective changes in prodromal disease. We report preliminary differences in metrics of heart rate variability (HRV) before and during routine cognitive testing.Method: We enrolled 50 participants from the Wake Forest Alzheimer’s Disease Research Center to wear continuous ECG devices during their visit to assess time and frequency domain based metrics of HRV over 5 minutes at rest and during cognitive testing. We used linear mixed effects models adjusted for age, sex, race, education, and APOE genotype to estimate the effect of condition (rest vs. cognitive testing) on HRV by cognitive status.Result: The sample (n=50) included 39 (78%) individuals adjudicated as having normal cognition (NC), 11 (22%) had MCI, 72% women, 12% Black, 86% White, and 2% Asian. The average age was 73±7 years old, and average education was 15.5±2.6 years. There were no significant differences in time‐ or frequency‐based metrics of HRV between rest and cognitive testing in the total sample (Figure 1). MCI tended towards lower root mean square of successive differences (RMSSD; p=0.11) and higher low‐frequency/high‐frequency (LF/HF) ratio (p=0.062) at rest. RMSSD (p=0.05) but not LF/HF (p=0.99) remained lower during cognitive testing (Table 1, Figure 2).Conclusion: Preliminary findings from our ongoing study using gold‐standard continuous ECG‐tracing during routine cognitive testing suggest no differences in HRV during the rest and cognitive testing conditions among the total sample, but may preliminarily suggest a shift to higher sympathetic and lower parasympathetic tone in participants with MCI.

  • Open Access

    Social genomics, cognition, and well‐being during the COVID‐19 pandemic

    by James R. Bateman, Sudarshan Krishnamurthy, Ellen E. Quillen, Christian E. Waugh, Kiarri N. Kershaw, Samuel N. Lockhart, Timothy M. Hughes, Teresa E. Seeman, Steve W. Cole, Suzanne Craft

    INTRODUCTION: Adverse psychosocial exposure is associated with increased pro‐inflammatory gene expression and reduced type‐1 interferon gene expression known as the conserved transcriptional response to adversity (CTRA). CTRA is not well‐studied in cognitive impairment but may contribute to late‐life cognitive decline.METHODS: We examined perceived stress, loneliness, well‐being, and the impact of coronavirus disease 2019 (COVID‐19) and the relationship to the expression of genes associated with the CTRA. Mixed‐effect linear models were used to quantify associations between psychosocial variables and CTRA gene expression.RESULTS: Eudaimonic well‐being (EWB) was inversely associated with CTRA gene expression in participants with both normal cognition (NC) and mild cognitive impairment (MCI). Self‐reported coping strategies differed by cognitive status and variably impacted CTRA gene expression.DISCUSSION: EWB is an important correlate of stress, even in people with MCI. The prodromal cognitive decline appears to moderate the significance of coping strategies as a correlate of CTRA gene expression.Highlights: Conserved transcriptional response to adversity (CTRA) gene expression is higher with lower eudaimonic well‐being. Eudaimonic well‐being was important in both participants with normal cognition and those with mild cognitive impairment. Coping strategies and impact on CTRA gene expression differed by cognitive status. Loneliness in a population with relatively low loneliness scores did not impact CTRA gene expression.


  • Open Access

    Impact of neighborhood disadvantage on cardiometabolic health and cognition in a community‐dwelling cohort

    by Sudarshan Krishnamurthy, Lingyi Lu, Christian J. Johnson, Laura D. Baker, Xiaoyan Leng, Sarah A. Gaussoin, Timothy M. Hughes, Da Ma, Allison Caban‐Holt, Goldie S. Byrd, et al.

    INTRODUCTION: Neighborhood disadvantage may be an important determinant of cardiometabolic health and cognitive aging. However, less is known about relationships among individuals with mild cognitive impairment (MCI).METHODS: The objective of this study is to investigate the relationship between neighborhood disadvantage measured by national Area Deprivation Index (ADI) rank with measures of cardiometabolic health and cognition among Wake Forest (WF) Alzheimer's Disease Research Center (ADRC) participants, with and without MCI.RESULTS: ADI was positively associated with blood pressure and cardiometabolic index (CMI), and negatively associated with global and Preclinical Alzheimer's Cognitive Composite (PACC5) scores, in cognitively unimpaired (CU) individuals. ADI was only positively associated with hemoglobin A1c (HbA1c) in MCI.DISCUSSION: Neighborhood disadvantage is associated more strongly with measures of cardiometabolic health and cognition among CU individuals rather than MCI. These findings demonstrate a need for structural solutions to address social determinants of health in an attempt to reduce cardiometabolic and cognitive risks.